Cardiff Oncology, Inc. (CRDF)
0.9073
-0.02
(-2.23%)
USD |
NASDAQ |
Oct 23, 16:00
0.9006
-0.01
(-0.74%)
After-Hours: 20:00
Cardiff Oncology EPS Diluted (Quarterly) : -0.1351 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.1351 |
| March 31, 2026 | -0.1807 |
| December 31, 2025 | -0.1064 |
| September 30, 2025 | -0.1684 |
| June 30, 2025 | -0.2097 |
| March 31, 2025 | -0.202 |
| December 31, 2024 | -0.2135 |
| September 30, 2024 | -0.2531 |
| June 30, 2024 | -0.2629 |
| March 31, 2024 | -0.2242 |
| December 31, 2023 | -0.2091 |
| September 30, 2023 | -0.2179 |
| June 30, 2023 | -0.2497 |
| March 31, 2023 | -0.2513 |
| December 31, 2022 | -0.1948 |
| September 30, 2022 | -0.1979 |
| June 30, 2022 | -0.2413 |
| March 31, 2022 | -0.2544 |
| December 31, 2021 | -0.2327 |
| September 30, 2021 | -0.1749 |
| June 30, 2021 | -0.1745 |
| March 31, 2021 | -0.1395 |
| December 31, 2020 | -0.1857 |
| September 30, 2020 | -0.1929 |
| June 30, 2020 | -0.5104 |
| Date | Value |
|---|---|
| March 31, 2020 | -0.4132 |
| December 31, 2019 | -0.5101 |
| September 30, 2019 | -0.7123 |
| June 30, 2019 | -0.7639 |
| March 31, 2019 | -1.023 |
| December 31, 2018 | -1.087 |
| September 30, 2018 | -1.098 |
| June 30, 2018 | -5.28 |
| March 31, 2018 | -6.232 |
| December 31, 2017 | -4.32 |
| September 30, 2017 | -8.64 |
| June 30, 2017 | -18.72 |
| March 31, 2017 | -23.04 |
| December 31, 2016 | -24.48 |
| September 30, 2016 | -24.48 |
| June 30, 2016 | -24.48 |
| March 31, 2016 | -25.92 |
| December 31, 2015 | -18.72 |
| September 30, 2015 | -16.56 |
| June 30, 2015 | -29.52 |
| March 31, 2015 | -23.76 |
| December 31, 2014 | -18.00 |
| September 30, 2014 | -20.16 |
| June 30, 2014 | -4.32 |
| March 31, 2014 | -12.24 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
| Alnylam Pharmaceuticals, Inc. | 1.207 |
| Anika Therapeutics, Inc. | 0.2412 |
| Savara, Inc. | -0.1587 |
| Vericel Corp. | 0.0422 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -9.232M |
| Revenue (Quarterly) | 0.104M |
| Total Expenses (Quarterly) | 9.336M |
| Enterprise Value | 28.09M |
| Gross Profit Margin (Quarterly) | -113.5% |
| Profit Margin (Quarterly) | -8.88K% |
| Earnings Yield | -65.09% |
| Normalized Earnings Yield | -65.08 |